Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke’s cell morphology

Abstract

PurposeMCM7 (minichromosome maintenance complex component 7), a DNA replication licensing factor, is a host gene for the oncogenic miR-106b~25 cluster. It has been recently revealed as a relevant prognostic biomarker in a variety of cancers, including pituitary adenomas. The purpose of this study was to assess whether miR-106b~25 and MCM7 levels correlate with tumor invasiveness in a cohort of ACTH-immunopositive adenomas.MethodsTissue samples were obtained intraoperatively from 25 patients with pituitary adenoma. Tumor invasiveness was assessed according to the Knosp grading scale. MCM7, Ki-67 and TP53 levels were assessed by immunohistochemical staining, while the expression of miR-106b-5p, miR-93-5p, miR-93-3p and miR-25-3p were measured using quantitative real-time PCR performed on RNA isolated from FFPE tissues.ResultsWe have found a significant increase in MCM7 and Ki-67 labeling indices in invasive ACTHomas. Moreover, MCM7 was ubiquitously overexpressed in Crooke’s cell adenomas. The expression of miR-93-5p was significantly elevated in invasive compared to noninvasive tumors. In addition, all four microRNAs from the miR-106b~25 cluster displayed marked upregulation in Crooke’s cell adenomas. Remarkably, MCM7 and miR-106b-5p both strongly correlated with Knosp grade. A combination of MCM7 LI and miR-106b~25 cluster expression was able to accurately differentiate invasive from noninvasive tumors and had a significant discriminatory ability to predict postoperative tumor recurrence/progression.ConclusionsmiR-106b~25 and its host gene MCM7 are potential novel biomarkers for invasive ACTH-immunopositive pituitary adenomas. Additionally, they are both significantly upregulated in rare Crooke’s cell adenomas and might therefore contribute to their aggressive phenotype.

Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival

“…both strands may be dysregulated concordantly in tumorigenesis 32 . For miR-145 and miR-30a 5p/3p pairs, analysis of RNAi and CRISPR screening data and miRNA-pathway interactions data across multiple cancer types showed they may regulate the survival/growth of numerous cancer cell lines by concordantly modulating the expression of cell cycle pathway genes.…”

Long noncoding RNA HOXA‐AS2 mediates microRNA‐106b‐5p to repress sepsis‐engendered acute kidney injury

“…[ 32 ] MiR‐106b‐5p is a mature form of miR‐106b, which is encoded by the miR‐106b‐25 cluster in the long arm 21 regions of human chromosome 7 (7q21). [ 33 ] The tumor specificity of miR‐106b‐5p has been broadly corroborated in all kinds of cancers. [ 34,35 ] Nonetheless, whether miR‐106b‐5p affects the roles of HOXA‐AS2 in sepsis‐evoked AKI remains unsolved.…”

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

“…In recent years, evidences have shown that miRNAs can target PD‐L1, thus altering the biological activities of tumors, such as invasion, migration, and immune evasion (Jia et al, 2017; Ashizawa et al, 2019). On the basis of the prediction of multiple online databases, we also found that PD‐L1 is a target gene of miR‐93‐5p, which is a member of the miR‐106b‐25 gene cluster that is abnormally expressed in various tumor tissues (Garbicz et al, 2017; Xiang et al, 2017). Previous evidence has identified the downregulation of miR‐93‐5p in CRC, suggesting the potential tumor‐suppressive role of miR‐93‐5p (Xiao et al, 2013; Yang et al, 2016).…”